Impact News +++ Mobility Global, Inc. declares $0.06 dividend (SeekingAlpha) +++ MOBILITY GLOBAL Aktie -5,54%

AB SCIENCE Aktie

>AB SCIENCE Aktienkurs

0.9 EUR -14.3% (TradegateBSX)

Ask: 0.94 EUR / 0 Stück

Bid: 0.88 EUR / 0 Stück

Tagesumsatz: 3184 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

AB SCIENCE Aktie über LYNX handeln

Intraday

1 Jahr

>AB SCIENCE Performance

1 Woche: +104,8%

1 Monat: +47,5%

3 Monate: +14,9%

6 Monate: -18,6%

1 Jahr: -14,7%

laufendes Jahr: -20,6%

>AB SCIENCE Aktie

Profil:

AB Science S.A. is a clinical-stage pharmaceutical company headquartered in Paris, France, founded in 2001. It specializes in the research, design, development, and marketing of innovative drugs targeting diseases with high unmet medical needs, parti..
>Volltext..

Insiderhandel:

>AB SCIENCE Kennzahlen

Aktien/ Unternehmen:

Analysten:

Bewertung:

Rentabilität:

Managementeffizenz:

>AB SCIENCE Peer Group

Gesundheit, Multiple Sklerose- Behandlung, Lungen- & Atemwegserkrankungen/ -behandlung, Neurologische Erkrankungen/ Schlaganfälle, Onkologie/ Krebs- Behandlung

>AB SCIENCE Chart & Kurs - Tradegate

>AB SCIENCE News

10.08.26 - 08:00	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million (GlobeNewswire EN)
	PRESS RELEASE...

06.08.26 - 16:33	The Next Billion-Dollar Opportunity in Alzheimer′s Disease Market: 6 Pipeline Therapies to Watch \| DelveInsight (PR Newswire)
	The Alzheimer's disease market dynamics are anticipated to change due to the expected launch of emerging therapies, such as Masupirdinea (Suven Life Sciences), Trontinemabb (Roche), Buntanetap (Annovis bio), Masitinib (AB Science), Remternetug (Eli Lilly), AUVELITY (AXS-05) (Axsome......

10.07.26 - 17:54	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs (GlobeNewswire EN)
	PRESS RELEASE...

01.07.26 - 08:06	AB Science announces the successful completion of a EUR 2.3 million private placement (GlobeNewswire EN)
	PRESS RELEASE...

29.06.26 - 08:03	AB Science reports completion of the step 3 of phase 1, evaluating the combination of AB8939 with venetoclax for the treatment of refractory or relapsed AML (GlobeNewswire EN)
	PRESS RELEASE...

17.06.26 - 18:09	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042 (GlobeNewswire EN)
	PRESS RELEASE...

09.06.26 - 18:51	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS (GlobeNewswire EN)
	PRESS RELEASE...

02.06.26 - 18:09	AB Science : Stonegate Capital Partners updates its coverage of AB Science′s stock with a target price of EUR 4.25 per share (GlobeNewswire EN)
	PRESS RELEASE...

25.05.26 - 18:09	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share (GlobeNewswire EN)
	PRESS RELEASE...

13.05.26 - 19:39	AB Science reports its revenues for the year 2025 and provides an update on its activities (GlobeNewswire EN)
	PRESS RELEASE...

29.04.26 - 08:06	AB Science announces the successful completion of a EUR 3.2 million private placement (GlobeNewswire EN)
	PRESS RELEASE...

27.04.26 - 18:09	AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors (GlobeNewswire EN)
	PRESS RELEASE...

20.04.26 - 21:36	AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients (GlobeNewswire EN)
	PRESS RELEASE...

16.04.26 - 19:24	AB Science provides an update on its clinical development program. (GlobeNewswire EN)
	PRESS RELEASE...

24.02.26 - 18:06	AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS (GlobeNewswire EN)
	PRESS RELEASE...

10.02.26 - 16:06	Reportable, Inc.: Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB) (Newsfile)
	Dallas, Texas--(Newsfile Corp. - February 10, 2026) - AB Science S.A. (ENXTPA: AB): Stonegate Capital Partners Initiates Coverage on AB Science S.A. (ENXTPA: AB). AB Science is a late-stage biotec......

09.02.26 - 18:09	AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors (GlobeNewswire EN)
	PRESS RELEASE...

29.01.26 - 18:03	AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer (GlobeNewswire EN)
	PRESS RELEASE...

21.01.26 - 18:06	AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041 (GlobeNewswire EN)
	PRESS RELEASE...

07.01.26 - 18:06	AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia (GlobeNewswire EN)
	PRESS RELEASE...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Überalterung ist vor allem ein Problem der leitenden Gremien. - Dr. Gerhard Kocher

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram